Helixgate

Helixgate

Uncategorized

Kardigan extends biotech’s streak of big IPOs with $400M haul

Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to BioPharma Dive data.

Read More

Published

on

Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to BioPharma Dive data.

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Denali sells FDA voucher for $195M to support neurodegenerative pipeline

Published

on

Denali Therapeutics is the latest company to sell a priority review fast pass for an elevated price after the program was renewed earlier this year.

Continue Reading

Uncategorized

US launches investigation into German drug pricing, citing unfair R&D burden

Published

on

The U.S. government has argued that it pays too much of biopharma R&D costs, demanding that other high-income countries contribute fairly to global innovation efforts.

Continue Reading

Uncategorized

STAT+: Up and down the ladder: The latest comings and goings

Published

on

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going.

And here is our regular feature in which we highlight a different person each week. This time around, we note that Protego Biopharma hired Jae Kim as chief medical officer. Previously, he held the same roles at Septerna and Design Therapeutics.

But all work and no play can make for a dull chief medical officer.

Continue to STAT+ to read the full story…

Continue Reading
Advertisement

Trending